Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.
This global race for an effective vaccine is scary. This is what the news should be coveringhttps://t.co/okqw0SE7CM— Amiejour (@Beloved_Day1) August 21, 2020
The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the U.S. and Germany, they said in a statement.
The confirmation of their October goal, first announced last month, helped lift S&P 500 futures briefly on Friday as part of a drumbeat of positive news on inoculation efforts that have the potential to end the threat of damaging lockdowns.
The timeline would make the vaccine one of the fastest-moving in the world. Some analysts expect a vaccine to be approved for use by November in the U.S., a move which may give President Donald Trump a new foothold in the election.
Pfizer and BioNTech last month clinched a $2 billion deal to supply an initial 100 million doses of the vaccine to the U.S. Governments around the world are looking to lock up supplies of still-experimental candidates in hope of stabilizing local economies and stopping spread of the virus that’s taken almost 800,000 lives globally.
The U.S. Food and Drug Administration is tentatively planning an advisory panel to meet Oct. 22 to discuss a Covid-19 vaccine, though it has not specified which vaccines, or how many, will be scrutinized.
Some of the fast-moving efforts around the world have started evaluating efficacy in the final stage of testing, paving the way for regulatory signoff. Russia approved a vaccine dubbed Sputnik V earlier this month, developed by Moscow’s Gamaleya Institute and the sovereign Russian Direct Investment Fund, and plans to administer it widely in October although the shot is still in the midst of human testing. The move has drawn criticism from scientists over concern of mass inoculation being carried out when the drug’s safety profile remains unclear.
Vaccine frontrunners in China have shipped their shots to virus hotspots around the world like Brazil, Indonesia and Saudi Arabia to conduct final-stage trials.
State-owned drugmaker Sinopharm Group Co. said this week that the two inactivated vaccines developed by the company’s subsidiaries will be available as soon as the end of the year and will be priced at less than 1,000 yuan ($145) for two doses. Beijing-based vaccine maker Sinovac Biotech Ltd. expects its shot to win regulatory approval early next year.
- Photos of Kamala Harris visit to Ghana
- Mobile Money transactions in only 2 months of 2023 hit ¢264.1bn
- Speculation that NDC imposed its decision on Minority Caucus is untrue – Sammy Gyamfi
- We would all have sworn to Antoa if my dad was alive – Zanetor Rawlings
- Ghana records $752.8m trade surplus in first 2 months of 2023
- We’re committed to helping Ghana resolve current economic crisis – China assures
- Popular American filmmaker Spike Lee is in Ghana
- T-Bills auction: sales undersubscribed by 23%; interest rates remain stable
- BoG increases policy rate to 29.5%; loans to remain expensive
- Playback: Kamala Harris meets Akufo-Addo
- US commits $100m to help combat terrorism in coastal West Africa
- Ghana’s IMF programme: Paris Club, China, other creditors agree to form OCC
- Meet Jon Boafo, Ghana’s first international rower: A story of perseverance and dedication
- Economic activity contracts but consumer confidence improves – BoG
- British Council builds network for UK-Ghanaian students to access employable opportunities
- NPA boss calls on National Chief Imam
- I don’t know – Akufo-Addo on presence or otherwise of Al-Qaeda troops in Ghana
- Black kids in England 6 times more likely to be strip-searched by police
- Debt servicing relief: China pledges to support Ghana
- U.S government to send resident advisor to help Ghana attain debt sustainability
- The Texas preacher’s $24m Ponzi scheme
- Take advantage of digital tools to win in the age of the entrepreneur – UMB CEO urges graduates
- Ghanaian Farmer TV host attends Climate Change and Agriculture Conference in South Africa
- Elon Musk: Twitter says parts of source code leaked online
- Kamala Harris urges Ghana’s creditors to help meet debt obligation amid IMF talks